UroGen Pharma Ltd. Ordinary Shares (URGN) Stock Price

URGNStock

$34.56+104.13%52W

Market Cap$1.69B

P/E—

PEG Ratio—

Div yield—

Beta1.57

URGN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)52.96%

Price vs S&P 500 (4W)-18.67%

VGM Score61.93

Book Value / Share (Quarterly)$0.60

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)19.48%

Cash Flow / Share (Quarterly)$-3.26

Price vs S&P 500 (YTD)35.64%

Gross Margin (TTM)90.85%

Net Profit Margin (TTM)-51.73%

EPS (TTM)$-1.98

10-Day Avg Trading Volume1.25M

EPS Excl Extra (TTM)$-1.98

Revenue Growth (5Y)56.22%

EPS (Annual)$-3.19

ROI (Annual)-1319.29%

Gross Margin (Annual)88.66%

Net Profit Margin (5Y Avg)-161.00%

Cash / Share (Quarterly)$2.21

Revenue Growth QoQ (YoY)199.22%

ROA (Last FY)-76.57%

Revenue Growth TTM (YoY)100.27%

EBITD / Share (TTM)$-1.34

ROE (5Y Avg)-324.81%

Operating Margin (TTM)-35.32%

Cash Flow / Share (Annual)$-3.37

P/B Ratio66.21x

P/B Ratio (Quarterly)20.96x

Net Income / Employee (Annual)$-527,500

EV / Revenue (TTM)9.55x

Net Interest Coverage (TTM)-15.36x

ROA (TTM)-43.79%

EPS Incl Extra (Annual)$-3.19

Current Ratio (Annual)4.01x

Quick Ratio (Quarterly)3.20x

3-Month Avg Trading Volume0.85M

52-Week Price Return104.13%

Revenue / Employee (TTM)$648,600

Tangible BV / Share (Quarterly)$-1.36

P/S Ratio (Annual)15.39x

Asset Turnover (Annual)0.55x

52-Week High$50.81

Operating Margin (5Y Avg)-122.99%

EPS Excl Extra (Annual)$-3.19

CapEx CAGR (5Y)-25.03%

26-Week Price Return62.87%

Quick Ratio (Annual)3.34x

13-Week Price Return-14.09%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)3.80x

Enterprise Value$1.80B

Revenue / Share Growth (5Y)33.32%

Asset Turnover (TTM)0.85x

Revenue / Employee (Annual)$377,300

Inventory Turnover (Annual)0.97x

Pretax Margin (Annual)-139.74%

Cash / Share (Annual)$2.49

3-Month Return Std Dev56.11%

Gross Margin (5Y Avg)88.98%

Net Income / Employee (TTM)$-335,500

ROE (Last FY)-1319.29%

Net Interest Coverage (Annual)-7.00x

EPS Basic Excl Extra (Annual)$-3.19

Receivables Turnover (TTM)3.48x

Total Debt / Equity (Quarterly)4.77x

EPS Incl Extra (TTM)$-1.98

Receivables Turnover (Annual)4.11x

ROI (TTM)-41.46%

P/S Ratio (TTM)8.95x

Pretax Margin (5Y Avg)-158.27%

Revenue / Share (Annual)$2.28

Tangible BV / Share (Annual)$-3.86

Forward P/E21.78x

Price vs S&P 500 (52W)88.60%

Year-to-Date Return47.57%

5-Day Price Return-9.72%

EPS Normalized (Annual)$-3.19

ROA (5Y Avg)-70.37%

Net Profit Margin (Annual)-139.81%

Month-to-Date Return-14.94%

Cash Flow / Share (TTM)$-4.08

EBITD / Share (Annual)$-2.59

Operating Margin (Annual)-113.73%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-324.81%

LT Debt / Equity (Quarterly)4.77x

EPS Basic Excl Extra (TTM)$-1.98

P/B Ratio (Annual)25.38x

Inventory Turnover (TTM)1.09x

Pretax Margin (TTM)-51.98%

Book Value / Share (Annual)$0.37

Price vs S&P 500 (13W)-16.78%

Beta1.57x

P/FCF (Annual)484.04x

Revenue / Share (TTM)$3.75

ROE (TTM)-204.47%

52-Week Low$16.36

vGradeD

gGradeA

mGradeB

vgmGradeB

URGN Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 5, 2026	-$0.27	-$0.28	-5.66%(-$0.02)
Q1 2026	May 6, 2026	-$0.48	-$0.47	+2.59%(+$0.01)
Q4 2025	Mar 2, 2026	-$0.51	-$0.53	-3.63%(-$0.02)
Q3 2025	Nov 6, 2025	-$0.68	-$0.69	-1.05%(-$0.01)
Q2 2025	Aug 7, 2025	-$0.83	-$1.05	-26.72%(-$0.22)

URGN Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.29

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
URGNUroGen Pharma Ltd. Ordinary Shares	D	A	B	9.0x	100.3%	90.8%	—	$34.56
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About UroGen Pharma Ltd. Ordinary Shares

UroGen Pharma is a biopharmaceutical company specializing in non-muscle invasive urothelial cancer treatments. The company commercializes two FDA-approved products—Jelmyto and Zusduri (both mitomycin-based)—which leverage its proprietary RTGel sustained-release technology to enhance therapeutic efficacy. Revenue is derived from United States sales of these approved oncology products.

URGN Next Earnings Report

Report dateNov 5, 2026

QuarterQ3 2026

Report timeBMO

EPS estimate$0.09

Revenue estimate$90.58M

Also reporting on Nov 5, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

URGN Insider Transactions

SellSep 8, 2026
SMITH JASON DREW
General Counsel
Shares: 1,519Value: $64,618
SellSep 8, 2026
SCHOENBERG MARK
Officer
Shares: 871Value: $37,383
SellAug 20, 2026
SCHOENBERG MARK
Officer
Shares: 60,677Value: $2.85M

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for September 2026

Companies in Related Industries

NVAXNovavax IncBiological Products
ALVOAlvotech Ordinary SharesBiological Products
OLNOlin Corp.Chemicals
MESOMesoblast Limited American Depositary SharesBiological Products
VIRVir Biotechnology, Inc. Common StockBiological Products
NTLAIntellia Therapeutics, IncIn Vitro Diagnostics
MAZEMaze Therapeutics, Inc. Common StockBiological Products
IMCRImmunocore Holdings plc American Depositary SharesBiological Products

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.3

Strong Buy

Consensus rating

52-Week Range

Low$16.36

High$50.81